These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1207280)

  • 1. [Evaluation of reliable pituitary suppression therapy through varying thyroid hormone dosage following total thyroidectomy due to a differentiated thyroid carcinoma].
    Wahl R; Hüfner M; Röher HD; Papke W
    Langenbecks Arch Chir; 1975; Suppl():469-74. PubMed ID: 1207280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hormone replacement in patients with carcinoma of the thyroid (author's transl)].
    Creutzig H; Kallfelz I; Haindl H; Schulle R; Hundeshagen H
    Dtsch Med Wochenschr; 1977 Dec; 102(48):1763-6. PubMed ID: 411647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Principals of hormone substitution in thyrectomized patients with carcinoma of the thyroid gland (author's transl)].
    Hüfner M; Munzinger H; Papke H; Barwich D; Bahner F; Schenk P; Röher D
    Radiologe; 1975 Jun; 15(6):245-50. PubMed ID: 809804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of the optimal thyroxine dose with the TRH test for replacement and suppression therapy].
    Erne P; Staub JJ; Althaus B; Fleig Y; Girard J
    Schweiz Med Wochenschr; 1983 Dec; 113(50):1922-3. PubMed ID: 6420884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preclinical and manifest hypothyroidism following thyroid gland operation].
    Csáky G; Balázs G; Varga J; Lukács G
    Z Gesamte Inn Med; 1982 Nov; 37(22):773-6. PubMed ID: 7184228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Can the thyrotropin (TSH) suppressive dose of L-thyroxine (T4) be individually predicted in athyroid patients?].
    Kainz H; Weissel M
    Acta Med Austriaca; 1990; 17(2-3):50-4. PubMed ID: 2120901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hormonal therapy in differentiated carcinoma of the thyroid gland].
    Francia G; Davì MV; Petroziello A; Sussi PL
    Chir Ital; 1994; 46(4):56-8. PubMed ID: 7882445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
    Lind P; Igerc I; Kohlfürst S
    Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Non-toxic nodular goiter: treatment and follow-up].
    Mereu P; Scala M; Schenone F; Schenone G; Comandini D; Gipponi M; Margarino G
    Acta Otorhinolaryngol Ital; 1995 Aug; 15(4):301-4. PubMed ID: 8928662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hormonal replacement therapy in women after surgery for thyroid cancer treated with suppressive doses of L-thyroxine].
    Jastrzebska H; Gietka-Czernel M; Zgliczyński S
    Wiad Lek; 2001; 54 Suppl 1():383-8. PubMed ID: 12182054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid function tests in euthyroid dogs treated with L-thyroxine.
    Panciera DL; MacEwen EG; Atkins CE; Bosu WT; Refsal KR; Nachreiner RF
    Am J Vet Res; 1990 Jan; 51(1):22-6. PubMed ID: 2105680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naming difficulties after thyroid stimulating hormone suppression therapy in patients with differentiated thyroid carcinoma: a prospective cohort study.
    Jin S; Yang YT; Bao W; Bai Y; Ai JW; Liu Y; Yong H
    Endocrine; 2019 Aug; 65(2):327-337. PubMed ID: 31056722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
    Sijanovic S; Karner I
    Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individually-tailored thyroxine requirement in the same patients before and after thyroidectomy: a longitudinal study.
    Del Duca SC; Santaguida MG; Brusca N; Gatto I; Cellini M; Gargano L; Verga Falzacappa C; Frattaroli FM; Virili C; Centanni M
    Eur J Endocrinol; 2015 Sep; 173(3):351-7. PubMed ID: 26092761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of hormone replacement therapy following total thyroidectomy in thyroid cancer--with special reference to the analysis of thyroid hormone peripheral effects, using indirect calorimetry].
    Nozaki H; Funahashi H; Sato Y; Imai T; Oike E; Kato M; Takagi H
    Nihon Geka Gakkai Zasshi; 1991 Dec; 92(12):1700-7. PubMed ID: 1809878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of thyroid function with hormone assays.
    Liewendahl K
    Ann Chir Gynaecol; 1983; 72(3):84-9. PubMed ID: 6414358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Criteria for suppressive dosage of thyroxine administered in thyroid cancer].
    Khmara IM; Demidchik IuE; Shapet'ko MN
    Vopr Onkol; 2004; 50(5):580-4. PubMed ID: 15715101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid-stimulating hormone suppression therapy for differentiated thyroid cancer: The role for a combined T3/T4 approach.
    Fussey JM; Khan H; Ahsan F; Prashant R; Pettit L
    Head Neck; 2017 Dec; 39(12):2567-2572. PubMed ID: 28960722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent therapy with L-thyroxine.
    Bernstein RS; Robbins J
    N Engl J Med; 1969 Dec; 281(26):1444-8. PubMed ID: 4187605
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.